Cytokinetics, Incorporated - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CYTK Nasdaq 2836 www.cytokinetics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cytokinetics, Incorporated

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst - Jan 22nd, 2025 8:43 pm
Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction - Jan 21st, 2025 12:30 pm
Cytokinetics Announces 2025 Corporate Milestones and Vision 2030 - Jan 13th, 2025 12:30 pm
Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Jan 6th, 2025 9:00 pm
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Jan 3rd, 2025 9:00 pm
Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy - Dec 23rd, 2024 12:30 pm
Why Cytokinetics Stock Was a Nearly 5% Winner Today - Dec 20th, 2024 10:25 pm
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China - Dec 20th, 2024 5:00 am
Calculating The Fair Value Of Cytokinetics, Incorporated (NASDAQ:CYTK) - Dec 19th, 2024 11:37 am
Why Is Cytokinetics (CYTK) Down 9.7% Since Last Earnings Report? - Dec 6th, 2024 4:31 pm
Cytokinetics Initiates Confirmatory Study on Heart Failure Drug - Dec 4th, 2024 5:30 pm
Sector Update: Health Care Stocks Mixed Late Afternoon - Dec 3rd, 2024 8:41 pm
FDA Accepts Cytokinetics' Application for Cardiovascular Drug - Dec 3rd, 2024 6:37 pm
Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction - Dec 3rd, 2024 12:30 pm
Cytokinetics to Participate in December Investor Conferences - Dec 2nd, 2024 9:00 pm
Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy - Dec 2nd, 2024 12:30 pm
Cytokinetics price target raised to $103 from $99 at Mizuho - Nov 22nd, 2024 11:51 am
Why Is Cytokinetics, Incorporated (CYTK) Among the Worst Performing Biotech Stocks in 2024? - Nov 21st, 2024 10:39 pm
Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan - Nov 20th, 2024 2:30 pm
Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer - Nov 19th, 2024 11:35 am